Zhongzhen Su | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhongzhen Su | Medicine | Best Researcher Award

The Fifth Affiliated Hospital of Sun Yat-sen University |China

Dr. Zhongzhen Su is a renowned medical professional with over two decades of expertise in abdominal ultrasound diagnosis and liver cancer interventional therapy. Currently serving as the Director of the Ultrasound Medicine Department at the Fifth Affiliated Hospital of Sun Yat-sen University, he has made pivotal contributions in early liver cancer detection and fibrosis assessment. Recognized as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, Dr. Su has significantly enhanced survival outcomes for cirrhotic patients through innovative imaging techniques.

Professional profile👤

Scopus

Strengths for the Awards✨

  1. Established Academic and Research Record:

    • 48 SCI publications with an H-index of 28 and 1,000+ citations, indicating consistent and influential contributions.

    • Highest publication impact factor of 14.3, demonstrating recognition in high-quality journals.

  2. Innovative Contributions:

    • Two patents (e.g., tumor ultrasound phantom, fibrosis prediction model) and innovative developments in liver cancer diagnostics and ablation.

    • Led 18 completed and 1 ongoing research projects, including National Natural Science Foundation grants.

  3. Clinical and Educational Impact:

    • Pioneered early detection and ultrasound-guided treatment of liver cancer, improving survival rates.

    • Trained over 50 postgraduates, indicating a significant contribution to academic mentorship.

  4. Recognitions and Leadership:

    • Recognized as a “High-level Talent in Zhuhai” and “Guangdong Outstanding Young Medical Talent”.

    • Serves as Director of Ultrasound Medicine and holds leadership roles in national professional associations.

  5. Interdisciplinary and AI Integration:

    • Engaged in AI-based fibrosis assessment and multicenter collaborations, showcasing forward-looking research alignment.

🎓 Education

Dr. Zhongzhen Su earned his Ph.D. in Imaging and Nuclear Medicine from Sun Yat-sen University, one of China’s top medical institutions. His academic foundation combines clinical depth with scientific rigor, forming the bedrock for his ongoing advancements in ultrasound-guided interventions and diagnostic radiology.

👨‍⚕️ Experience

With over 20 years of clinical and academic experience, Dr. Zhongzhen Su has held key roles, including Deputy Dean of the Fifth Affiliated Hospital and now Director of Ultrasound Medicine. His leadership has been instrumental in establishing state-of-the-art interventional ultrasound programs, supervising over 50 postgraduates, and leading multicenter clinical trials focused on liver health.

🔬 Research Interest On Medicine

Dr. Zhongzhen Su primary research interests lie in abdominal ultrasound diagnosis, interventional ultrasound for liver cancer, quantitative assessment of liver fibrosis, and post-ablation evaluation techniques. He is also exploring AI-based models for early-stage fibrosis and cancer detection, which promise transformative impacts in personalized medicine.

🏆 Awards

Dr. Zhongzhen Su is a three-time recipient of the Guangdong Science and Technology Awards 🏅, reflecting his leadership in ultrasound-guided interventional innovation. He has also been honored as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, distinctions reserved for top-tier professionals in the region’s medical community.

📚 Publications

1. Nomogram Using Bi-modal Imaging for Predicting Low-level HER2 Expression Status in Breast Cancer

  • Authors: Xingyu Liang, Jiamin Chen, Jiawei Tian, Xin Wen

  • Journal: European Journal of Radiology

  • Year: 2025

2. Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients

  • Authors: Yu Li, Sheng Li, Qing Li, Lingling Li, Jianhua Zhou

  • Journal: Korean Journal of Radiology

  • Year: 2025

  • Citations: 0​

3. Doppler Ultrasound Imaging and Shear Wave Elastography for Evaluation of Interstitial Fibrosis/Tubular Atrophy in IgA Nephropathy

  • Authors: Jiaxin Chen, Shuqing Wang, Qunyan Wu, Zhongzhen Su, Yuhong Lin

  • Journal: Abdominal Radiology

  • Year: 2025

4. Tertiary Lymphoid Structure Formation Induced by LIGHT-Engineered and Photosensitive Nanoparticles-Decorated Bacteria Enhances Immune Response Against Colorectal Cancer

  • Authors: Lijun Hu, Li Tan, Shaohui Deng, Honglin Gao, Yujie Jiang, Chen Qiu, Hui Chen, Zecong Xiao, Xintao Shuai, Zhongzhen Su

  • Journal: Biomaterials

  • Year: 2025

  • Citations: 6​

5. Histopathological Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma: Is It Reliable?

  • Authors: Liujun Li, Chaoqun Wu, Feile Ye, Zhou Xuan, Xiaoli Zhang, Jianping Li, Jia Zhou, Zhongzhen Su

  • Journal: World Journal of Gastroenterology

  • Year: 2025

6. Radiomics Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma Using 3D Ultrasound and Whole-Slide Image Fusion

  • Authors: Liujun Li, Shaodong Wang, Jiaxin Chen, Yao Lu, Zhongzhen Su

  • Journal: Small Methods

  • Year: 2025

7. Model Based on Ultrasound and Clinicopathological Characteristics for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

  • Authors: Xin Wen, Jiamin Chen, Jing Zhong, Yuhong Lin, Zhongzhen Su

  • Journal: Quantitative Imaging in Medicine and Surgery

  • Year: 2024

  • Citations: 1​

8. Development and Validation of an Individualized Nomogram for Predicting Patent Foramen Ovale-Associated Stroke: Patent Foramen Ovale Morphology-Based Analysis

  • Authors: Qin Zhang, Mochao Xiao, Wuzhu Lu, Zhongzhen Su, Xiaobo Chen

  • Journal: Echocardiography

  • Year: 2024

🧾 Conclusion

In summary, Dr. Zhongzhen Su stands out as a visionary ultrasound expert and medical educator, having redefined interventional standards in liver cancer therapy and fibrosis evaluation. His trailblazing research, prolific publication record, and dedication to clinical excellence make him an ideal nominee for the Best Researcher Award at the FORENSIC SCIENTIST AWARDS. 🏅🔍

Mohamad Taleuzzaman | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Mohamad Taleuzzaman | Pharmacology | Best Researcher Award

Maulana Azad University | India

Dr. Mohamad Taleuzzaman is a distinguished academician and researcher in the field of pharmaceutical chemistry. With a career spanning over 15 years, he has contributed significantly to pharmaceutical education, research, and administration. Currently serving as a Professor and Head of the Department at Maulana Azad University, Jodhpur, his expertise lies in pharmaceutical analysis, drug development, and bioanalytical research. Passionate about scientific innovation, he has played a vital role in mentoring students and advancing pharmaceutical sciences.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

  • Extensive Research Contributions – Dr. Taleuzzaman has numerous publications in high-impact journals, showcasing his active engagement in research.

  • Diverse Research Interests – His work spans pharmaceutical chemistry, nanotechnology, molecular docking, and bioanalytical method development.

  • Academic Leadership – Serving as a Professor and HOD, he has contributed to institutional development and research coordination.

  • Patent Holder – His patent on a polymeric nano scaffold for anti-diabetic applications highlights his innovation.

  • Mentorship – He has successfully guided Ph.D. and M.Pharm students, contributing to academic growth.

  • Strong Administrative Experience – Coordinating academic inspections, examinations, and regulatory compliance.

Education 🎓

Dr. Taleuzzaman pursued his Ph.D. in Pharmaceutical Chemistry from Glocal University, Saharanpur, in 2018. He completed his M.Pharm in Pharmaceutical Analysis from Jamia Hamdard, New Delhi, securing a first-class distinction with 73.84% in 2007. His academic journey began with a B.Pharm from the same institution in 2005. Additionally, he qualified for the GATE examination in 2005 with an impressive percentile of 92.49, further solidifying his strong foundation in pharmaceutical sciences.

Professional Experience 💼

With over 15 years of professional experience, Dr. Taleuzzaman has held key positions in both academia and the pharmaceutical industry. Since 2019, he has been serving as a Professor and HOD at Maulana Azad University, Jodhpur. Prior to this, he worked as an Associate Professor at Glocal School of Pharmacy, Saharanpur, and as an Assistant Professor at KIET School of Pharmacy, Ghaziabad. His industrial experience includes roles such as Product Development Manager at Ultra Biolabs Pvt. Ltd., Chandigarh, and Quality Officer at Ali & Abdul Karim Trading Co., Oman.

Research Interests On Pharmacology 📚

Dr. Taleuzzaman’s research is centered on pharmaceutical analysis, drug formulation, and bioanalytical method development. His Ph.D. research focused on the extraction, characterization, and quantification of thymoquinone and eugenol from Nigella sativa and Myristica fragrans. He has also explored novel drug delivery systems, nanotechnology applications in pharmaceuticals, and synthetic methodologies for bioactive compounds.

Awards & Recognitions 🏆

Dr. Taleuzzaman has been recognized for his contributions to pharmaceutical sciences and academic excellence. His innovative research has led to a patent titled “Sitagliptin loaded polymeric nano scaffold for enhanced anti-diabetic performance” (Patent number: 2021104076). He has also been actively involved in coordinating major academic accreditations such as PCI, UGC, and NAAC inspections at leading pharmacy institutions.

Publications 📄

Dr. Taleuzzaman has published extensively in high-impact journals. Some of his notable research articles include:

  • Ultra performance liquid chromatography (UPLC)-a review
    Authors: M Taleuzzaman, S Ali, SJ Gilani, SS Imam, A Hafeez
    Year: 2015
    Citations: 133

  • Limit of blank (LOB), limit of detection (LOD), and limit of quantification (LOQ)
    Author: M Taleuzzaman
    Year: 2018
    Citations: 88

  • Eugenol as a potential drug candidate: A review
    Authors: M Taleuzzaman, P Jain, R Verma, Z Iqbal, MA Mirza
    Year: 2021
    Citations: 79

  • Clarithromycin-loaded ocular chitosan nanoparticle: formulation, optimization, characterization, ocular irritation, and antimicrobial activity
    Authors: M Bin-Jumah, SJ Gilani, MA Jahangir, A Zafar, S Alshehri, M Yasir, C Kala, …
    Year: 2020
    Citations: 70

  • Quality by design (Qbd) assisted development of phytosomal gel of aloe vera extract for topical delivery
    Authors: P Jain, M Taleuzzaman, C Kala, D Kumar Gupta, A Ali, M Aslam
    Year: 2021
    Citations: 48

  • Nano phytomedicine based delivery system for CNS disease
    Authors: MA Jahangir, C Anand, A Muheem, SJ Gilani, M Taleuzzaman, A Zafar, …
    Year: 2020
    Citations: 44

  • Thymoquinone-entrapped chitosan-modified nanoparticles: formulation optimization to preclinical bioavailability assessments
    Authors: I Rahat, SS Imam, M Rizwanullah, S Alshehri, M Asif, C Kala, …
    Year: 2021
    Citations: 36

  • Benzothiazole incorporated thiazolidin-4-ones and azetidin-2-ones derivatives: Synthesis and in vitro antimicrobial evaluation
    Authors: SJ Gilani, K Nagarajan, SP Dixit, M Taleuzzaman, SA Khan
    Year: 2016
    Citations: 30

  • Phytosomal gel of Manjistha extract (MJE) formulated and optimized with central composite design of Quality by Design (QbD)
    Authors: M Taleuzzaman, A Sartaj, D Kumar Gupta, SJ Gilani, MA Mirza
    Year: 2023
    Citations: 29

  • Formulation and evaluation of thymoquinone niosomes: Application of developed and validated RP-HPLC method in delivery system
    Authors: SJ Gilani, SS Imam, A Ahmed, S Chauhan, MA Mirza, M Taleuzzaman
    Year: 2019
    Citations: 28

Conclusion 🔗

Dr. Mohamad Taleuzzaman’s dedication to pharmaceutical research and education has made a profound impact on the field. His work in drug development, bioanalytical chemistry, and nanotechnology has contributed to the advancement of pharmaceutical sciences. As a mentor, researcher, and academic leader, he continues to inspire and shape the future of pharmaceutical research.

Zhanbo Qu | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhanbo Qu | Medicine | Best Researcher Award

Huzhou central hospital | China

Dr. Qu Zhanbo is a dedicated medical professional at Huzhou Central Hospital, with a focus on microbiology, oncology, and gastroenterology. As a researcher, Dr. Qu has made significant contributions to the scientific community, publishing multiple papers in esteemed journals. His academic journey is marked by exceptional achievements, including being recognized as a top graduate innovative talent during his master’s studies.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Research Productivity: Qu Zhanbo has published 2 SCI papers as the first author, 3 SCI papers as a total of first author, and contributed to 16 SCI papers overall. This demonstrates consistent research output and collaboration.

  • Interdisciplinary Focus: His research spans microbiology, oncology, and gastroenterology — fields with significant impact on healthcare, especially in understanding colorectal cancer risk.

  • Recognition and Innovation: Awarded as a top graduate Innovative Talent during his master’s studies, reflecting early recognition for his research potential.

  • Patent Development: Involved in the development of dissolving microneedles of Clostridium butyricum and oxaliplatin, indicating a focus on translational research and innovation.

  • Diverse Publications: Contributions to reputable journals like Aging and Disease, Aging-US, Digestion, and Microbial Biotechnology highlight his research’s acceptance in well-regarded scientific communities.

Education 🎓

Dr. Qu Zhanbo pursued his medical education with a deep interest in understanding complex diseases and their microbial interactions. His academic path laid the foundation for his subsequent research endeavors, where he explored the intersection of microbiology and oncology.

Experience 💼

Currently serving at Huzhou Central Hospital, Dr. Qu combines clinical practice with groundbreaking research. His work spans various domains, including the association of Peptostreptococcus stomatis with colorectal cancer risk. Over the years, he has authored multiple SCI papers and contributed extensively to scientific literature, showcasing his expertise and commitment to advancing medical knowledge.

Research Interests On Medicine🔬

Dr. Qu’s research interests lie at the crossroads of microbiology, oncology, and gastroenterology. His investigations delve into microbial influences on cancer development, aiming to uncover novel insights that could lead to improved diagnostic and therapeutic strategies.

Awards 🏆

Dr. Qu’s academic and research excellence have been recognized through several accolades, including being awarded as a top graduate innovative talent during his master’s studies. This honor reflects his exceptional contributions to scientific inquiry and innovation.

Publications 📖

Dr. Qu has an impressive publication record, with notable papers such as:

  1. Multiple primary malignancies and gut microbiome

    • Year: 2025

    • Authors: Yinhang Wu, Zhanbo Qu, Zheng Wu, Jing Zhuang, Yingchen Wang, Zefeng Wang, Jian Chu, Quan Qi, Shuwen Han

  2. Fecal occult blood affects intestinal microbial community structure in colorectal cancer

    • Year: 2025

    • Authors: Wu Guodong, Wu Yinhang, Wu Xinyue, Shen Hong, Chu Jian, Qu Zhanbo, Han Shuwen

  3. Aging Gut Microbiome in Healthy and Unhealthy Aging

    • Year: 2024

    • Authors: Zhanbo Qu

  4. Classification of Colorectal Cancer Subtypes Based on Endoplasmic Reticulum Stress

    • Year: 2024

    • Authors: Zhanbo Qu, Jian Chu, Yinhang Wu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  5. Escherichia coli on colorectal cancer: A two‐edged sword

    • Year: 2024 (October)

    • Authors: Chu Jian, Wu Yinhang, Zhuang Jing, Qu Zhanbo, Wang Zefeng, Shuwen Han

  6. Deep learning application in prediction of cancer molecular alterations based on pathological images: a bibliographic analysis via CiteSpace

    • Year: 2024 (October)

    • Authors: Yu Xiaojian, Qu Zhanbo, Chu Jian, Wang Zefeng, Liu Jian, Liu Jin, Pan Yuefen, Han Shuwen

  7. Third-generation PacBio sequencing to explore gut bacteria and gender in colorectal cancer

    • Year: 2024 (July)

    • Authors: Sheng Yu, Jian Chu, Yinhang Wu, Jing Zhuang, Zhanbo Qu, Yifei Song, Xinyue Wu, Shuwen Han

  8. Age and aging process alter the gut microbes

    • Year: 2024 (April 8)

    • Authors: Qu Zhanbo, Zhuang Jing, Han Shugao, Wu Yinhang, Chu Jian, Yu Xiang, Zhao Feimin, Liu Jian, Wu Xinyue, Wu Wei et al.

  9. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T‐cell costimulator as a crucial immune checkpoint molecule

    • Year: 2024 (March)

    • Authors: Jian Chu, Yinghang Wu, Zhanbo Qu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  10. Identification of enterotype and its predictive value for patients with colorectal cancer

  • Year: 2024 (February 27)

  • Authors: Li Qingbo, Zhuang Jing, Qu Zhanbo, Chu Jian, Song Yifei, Wu Yinhang, Han Shuwen

Conclusion 🔝

Dr. Qu Zhanbo stands out as a passionate researcher and dedicated doctor whose work bridges clinical practice and scientific exploration. His contributions to microbiology, oncology, and gastroenterology continue to shape the understanding of disease mechanisms and pave the way for future innovations in medical science.

Xiaoling Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Kevin Pak | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Kevin Pak | Medicine | Best Researcher Award

Transplant Hepatology Fellow | UCLA | United States

Dr. Kevin C. Pak, M.D., is a distinguished transplant hepatologist affiliated with the Pflieger Liver Institute at the David Geffen School of Medicine at UCLA. With a strong background in internal medicine, gastroenterology, and hepatology, Dr. Pak has dedicated his career to advancing liver disease treatment and transplantation. His contributions to academic research and clinical practice have earned him recognition in the medical community.

Profile👤

Google Scholar

Scopus

Strengths for the Awards✨

✅ Exceptional Research Contributions: Dr. Pak has an extensive portfolio of peer-reviewed publications in prestigious journals, covering a range of topics in gastroenterology, hepatology, and military medicine. His research on hepatitis B, hepatocellular carcinoma, liver transplantation, and inflammatory bowel disease is particularly noteworthy.

✅ Clinical and Academic Leadership: As an Assistant Professor at USUHS and a former Chief Fellow in a gastroenterology fellowship, Dr. Pak has demonstrated strong mentorship and leadership in academic medicine. His contributions to teaching and training future physicians further emphasize his dedication to research and education.

✅ Recognized Excellence: Multiple honors and awards, including the AASLD Emerging Liver Scholar Award (2019) and Resident Researcher of the Year, highlight his significant impact in the field. His invited presentations and poster sessions at national and international conferences further validate his research reputation.

✅ Interdisciplinary and Military Medicine Contributions: His unique background in military medicine and research contributions in military healthcare settings (e.g., inflammatory bowel disease in active-duty personnel) provide a broader impact beyond civilian medicine.

Education 🎓

Dr. Pak began his academic journey at the United States Military Academy (USMA) in West Point, New York, earning a B.S. in Life Sciences. He then pursued his medical degree at the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. His postgraduate training includes an Internal Medicine Residency at Walter Reed National Military Medical Center, followed by a Gastroenterology & Hepatology Fellowship at Naval Medical Center San Diego. He further specialized in Transplant Hepatology through a fellowship at the Pflieger Liver Institute at UCLA.

Experience 💼

Dr. Pak has held several academic positions, including Assistant Professor of Medicine and Teaching Fellow at USUHS. He is actively involved in medical education, mentoring students and residents. His clinical expertise spans hepatology, transplant medicine, and gastroenterology, making him a key contributor to the field. Additionally, Dr. Pak has served in the military, where he provided medical services in critical care settings.

Research Interests On Medicine🔬

Dr. Pak’s research focuses on liver disease, hepatocellular carcinoma, chronic hepatitis B, and liver transplantation. He is particularly interested in optimizing treatment strategies for liver disease and investigating emerging therapies. His work contributes to advancements in hepatology, improving patient outcomes and clinical practices.

Awards 🏆

Dr. Pak has received numerous accolades throughout his career. He was honored with the Resident Researcher of the Year Award and the AASLD Emerging Liver Scholar Award. His excellence in teaching earned him the James J. Leonard Award for Excellence in Teaching. In his military service, he received commendations such as the Navy/Marine Corps Commendation Medal and the Joint Service Commendation Medal.

Publications 📚

Dr. Pak has authored multiple peer-reviewed publications in prestigious journals. His notable works include:

  • Systematic review of safety of selective androgen receptor modulators in healthy adults: implications for recreational users

    • Authors: JD Vignali, KC Pak, HR Beverley, JP DeLuca, JW Downs, AT Kress, …
    • Publication Year: 2023
    • Citations: 38

  • Wilson’s disease and iron overload: pathophysiology and therapeutic implications

    • Authors: K Pak, S Ordway, B Sadowski, M Canevari, D Torres
    • Publication Year: 2021
    • Citations: 23

  • Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018

    • Authors: ZC Junga, A Mertz, K Pak, M Singla
    • Publication Year: 2023
    • Citations: 9

  • The Patterns and Associated Cost of Serologic Testing for Helicobacter pylori in the U.S. Military Health System

    • Authors: K Pak, Z Junga, A Mertz, M Singla
    • Publication Year: 2020
    • Citations: 6

  • State of the art: Test all for anti-hepatitis D virus and reflex to hepatitis D virus RNA polymerase chain reaction quantification

    • Authors: E Umukoro, JJ Alukal, K Pak, J Gutierrez
    • Publication Year: 2023
    • Citations: 5

  • Occult HBV infection: a case series at a military treatment facility

    • Authors: K Pak, S Ordway, D Torres
    • Publication Year: 2020
    • Citations: 4

  • An acute presentation of chronic gastric volvulus

    • Authors: K Pak, Z Junga, P Young
    • Publication Year: 2020
    • Citations: 4

  • Decades of cough: Delayed recognition of atypical cystic fibrosis in an adult patient

    • Authors: A Chandel, K Pak, S Dooley, K Salazar
    • Publication Year: 2020
    • Citations: 3

  • A small blemish: isotretinoin-induced microscopic colitis

    • Authors: LR Dukate, K Pak, W O’Connell, Z Junga
    • Publication Year: 2022
    • Citations: 2

  • A Case of Whipple’s Disease With Concomitant Esophageal Candidiasis

    • Authors: R Choi, A Pazevic, K Pak, M Skaret, A Bachmann, R Wilkerson
    • Publication Year: 2024
    • Citations: 1

Conclusion 🔍

Dr. Kevin C. Pak, M.D., is a dedicated physician, educator, and researcher in hepatology and gastroenterology. His commitment to advancing liver disease treatment, coupled with his academic and clinical expertise, makes him a key figure in the field. Through his research, mentorship, and clinical practice, Dr. Pak continues to contribute significantly to medical science and patient care.

Guowei Zheng | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Guowei Zheng | Medicine | Best Researcher Award

Yunnan University of Chinese Medicine | China

Dr. Guowei Zheng is a distinguished professor at Yunnan University of Chinese Medicine, specializing in medicinal plant research. His work focuses on the collection, evaluation, and breeding of medicinal plant germplasm, as well as understanding plant responses to stress and exploring the biosynthetic pathways of medicinal ingredients in Chinese herbs. With extensive academic experience spanning over a decade, Dr. Zheng has made significant contributions to plant biology through multiomics approaches and phytochemical studies.

Profile👤

ORCID

Strengths for the Awards✨

  • Strong Research Output 📚

    • Dr. Zheng has published over 20 high-quality research papers in reputable journals, including BMC Plant Biology, Plant Diversity, PLoS ONE, and Phytochemistry.
    • His recent publications (2023–2025) demonstrate consistent research contributions, particularly in multi-omics, metabolomics, and medicinal plants.

  • Diverse Research Expertise 🔬

    • His work spans multiple critical areas, including medicinal plant breeding, stress response, and biosynthetic pathways of Chinese herbs.
    • His research on polyphyllin biosynthesis, glycerolipidome responses, and CO₂ elevation effects contributes to both fundamental science and applied plant biotechnology.

  • Academic and Professional Growth 📈

    • Rising from Assistant Professor (2010) to Full Professor (2021) at Yunnan University of Chinese Medicine.
    • Previous tenure at Kunming Institute of Botany, Chinese Academy of Sciences, a prestigious research institution.

🎓 Education

  • Ph.D. in Botany (2005–2010) – Kunming Institute of Botany, Chinese Academy of Sciences
  • Bachelor’s Degree in Biology (2001–2005) – Yunnan University

👨‍🏫 Experience

  • Professor (2021–Present) – Yunnan University of Chinese Medicine
  • Associate Professor (2018–2021) – Yunnan University of Chinese Medicine
  • Associate Professor (2016–2018) – Kunming Institute of Botany, Chinese Academy of Sciences
  • Assistant Professor (2010–2015) – Kunming Institute of Botany, Chinese Academy of Sciences

🔬 Research Interests On Medicine

  • 🌿 Medicinal Plant Germplasm – Collection, evaluation, and breeding of medicinal plant species
  • 💧 Plant Stress Response – Studying how medicinal plants adapt to environmental stressors
  • 🧪 Phytochemical Biosynthesis – Investigating synthesis pathways of medicinal compounds in Chinese herbs

🏆 Awards

(Please provide specific awards or recognitions received.)

📚 Publications

Dr. Zheng has published extensively in high-impact journals, contributing significantly to plant biology and phytochemistry.

  • Xu, P., Mi, Q., Zhang, X., Zhang, X., Yu, M., Gao, Y., Wan, X., Chen, Y., Li, Q., Chen, J., & Zheng, G. (2025). Dissection of transcriptome and metabolome insights into the polyphyllin biosynthesis in Paris. BMC Plant Biology, 25(1), 206.

  • Xu, P., Chen, J., Mi, Q., Li, W., Lu, Y., Luo, W., Yu, M., Zhang, X., Tu, Z., Xu, H., & Zheng, G. (2024). Metabolomics and transcriptomics profiling of three Paris species with varied polyphyllin compositions. Sci Data, 11(1), 1293.

  • Zheng, G., Li, W., Zhang, S., Mi, Q., Luo, W., Zhao, Y., Qin, X., Li, W., Pu, S., & Xu, F. (2023). Multiomics strategies for decoding seed dormancy breakdown in Paris polyphylla. BMC Plant Biology, 23(1), 247.

  • Li, W., Zhang, X., Pei, W., & Zheng, G. (2021). First Report of Root Rot Caused by Dactylonectria torresensis on Bletilla striata (Baiji) in Yunnan, China. Plant Disease, 0(0), PDIS-10-20-2166-PDN.

  • Liu, T., Chen, J., Xu, F., He, X., Yang, S., Zhu, Y., Li, W., & Zheng, G. (2020). Analysis of changes in the Panax notoginseng glycerolipidome in response to long-term chilling and heat. Plant Diversity, 42, 102-110.

  • Zheng, G., Cheng, J., & Li, W. (2020). Impacts of CO2 elevation on the physiology and seed quality of soybean. Plant Diversity, 42(1), 44-51.

  • Zheng, G., Luo, S., Li, S., Hua, J., Li, W., & Li, S. (2018). Specialized metabolites from Ageratina adenophora and their inhibitory activities against pathogenic fungi. Phytochemistry, 148, 57-62.

  • Zheng, G., & Li, W. (2017). Profiling membrane glycerolipids during gamma-ray-induced membrane injury. BMC Plant Biology, 17(1), 203.

  • Chen, J., Zheng, G., Zhang, Y., Aisa, H. A., & Hao, X. (2017). Phytotoxic Terpenoids from Ligularia cymbulifera Roots. Front Plant Sci, 7, 2033.

  • Zheng, G., Li, L., & Li, W. (2016). Glycerolipidome responses to freezing- and chilling-induced injuries: examples in Arabidopsis and rice. BMC Plant Biology, 16, 70.

  • Tang, T., Liu, P., Zheng, G., & Li, W. (2016). Two phases of response to long-term moderate heat: Variation in thermotolerance between Arabidopsis thaliana and its relative Arabis paniculata. Phytochemistry, 122, 81-90.

🔚 Conclusion

Dr. Guowei Zheng is a leading researcher in medicinal plant biology, with expertise in plant stress adaptation and bioactive compound biosynthesis. His contributions to plant sciences and phytochemistry continue to advance our understanding of medicinal herbs, making a significant impact on the field of traditional Chinese medicine and agricultural biotechnology.

Yinfeng Chen | Medicine | Women Researcher Award

Published on by Forensic Scientist

Ms. Yinfeng Chen | Medicine | Women Researcher Award

Attending physician | Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University | China

Dr. Yinfeng Chen is an attending physician at the Department of Nephrology, Hangzhou TCM Hospital, affiliated with Zhejiang Chinese Medical University. With over a decade of experience in clinical nephropathy, Dr. Chen has become a recognized expert in the field. She has actively contributed to various academic endeavors and plans to further her research at the Clinical Research Institute of China-Japan Friendship Hospital in 2024. Her expertise lies in kidney diseases, and she is dedicated to providing innovative treatments to improve patient outcomes.

Profile🔍

Scopus

Strengths for the Awards

  • Solid Academic and Professional Background: Yinfeng holds a postgraduate degree in clinical nephropathy from Zhejiang Chinese Medicine University and has 10 years of clinical experience. This provides a solid foundation for her work in the nephrology field.
  • Research Contributions: She has conducted significant research on chronic kidney disease and its correlation with conditions like stroke, diabetic kidney disease, FSGS, and chronic kidney failure. Her work contributes directly to improving patient outcomes and advancing the field of nephrology.
  • Clinical Application and Innovation: Her commitment to providing personalized treatment plans based on individual conditions demonstrates a practical approach to her research, enhancing the impact of her findings on real-world patient care.
  • Active Participation in Academic Activities: She is engaged in further research at the Clinical Research Institute of China-Japan Friendship Hospital, highlighting her dedication to continuous professional development and collaboration.
  • Published Research: Her research has been published in reputable journals (doi: 10.1080/0886022X.2025.2452219), contributing to the academic discourse in the nephrology field.
  • Yinfeng Chen has demonstrated considerable strength in her clinical and research endeavors, particularly in the area of nephrology. Her dedication to improving patient care and advancing the understanding of kidney diseases makes her a strong candidate for the “Women Researcher Award.” With further contributions in publications, patents, or leadership roles in academic organizations, her profile could become even more competitive.

Education 📚

Dr. Chen graduated from Zhejiang Chinese Medicine University with a postgraduate degree in clinical nephropathy. She has since accumulated substantial clinical experience, working in the nephrology department for over 10 years. Her academic journey has continuously been complemented by active participation in academic and research activities.

Experience💼

As an attending physician in nephrology, Dr. Yinfeng Chen has developed tailored treatment plans for patients, particularly in chronic kidney disease (CKD) and diabetic kidney disease. Her decade-long clinical experience has been enriched through various collaborations, including her upcoming research at the Clinical Research Institute of China-Japan Friendship Hospital.

Research Interest On Medicine 🔬

Dr. Chen’s research interests primarily focus on kidney diseases, including chronic kidney disease, stroke, diabetic kidney disease, and FSGS (focal segmental glomerulosclerosis). She has been exploring the correlation between chronic kidney disease and stroke, among other critical issues in nephrology, with a commitment to developing innovative therapies for better patient survival and treatment outcomes.

Awards🏆

Dr. Yinfeng Chen has been nominated for the prestigious “Women Researcher Award,” a recognition of her significant contributions to nephrology and medical research. Her dedication to enhancing kidney disease treatments through her research and clinical expertise makes her an ideal candidate for this award.

Publications📖

Dr. Chen has published several studies in prominent journals. One of her recent articles, titled “Correlation Between Chronic Kidney Disease and Stroke,” was published in the International Journal of Nephrology and Renovascular Disease in 2025. The article can be accessed here. Her work is also cited by numerous other research studies.

Conclusion🌱

With a proven track record in clinical nephrology and an unwavering commitment to advancing kidney disease research, Dr. Yinfeng Chen continues to make significant strides in the field. Her upcoming work and future endeavors promise to further improve kidney disease management and treatment.

Guoli Li | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Guoli Li | Medicine | Best Researcher Award

Researcher | Hunan Provincial People’s Hospital (The First-Affiliated Hospital of Hunan Normal University) | China

Dr. Guoli Li, Ph.D., is an Assistant Professor at Hunan Provincial People’s Hospital and the First Affiliated Hospital of Hunan Normal University, located in Changsha, China. With expertise in Molecular Medicine, Cancer Research, and Nephrology, Dr. Li has contributed extensively to the scientific community, focusing on cutting-edge advancements in medical research.

Profile

Google Scholar

Strengths for the Awards

  • Extensive Research Background:
    Dr. Guoli Li has a strong academic and research foundation in molecular medicine, cancer research, and nephrology, with significant experience at reputable institutions like the University of Texas MD Anderson Cancer Center and Hunan Normal University.
  • Diverse Publication Record:
    Dr. Li has authored numerous high-impact publications in peer-reviewed journals such as Frontiers in Oncology, Genes and Diseases, and BMC Nephrology. These papers cover critical topics like cancer biomarkers, glomerulopathy, and ferroptosis in cancer, demonstrating expertise in innovative and clinically relevant research.
  • Bibliometric Contributions:
    Contributions to bibliometric studies (e.g., research on ferroptosis and mitophagy) highlight Dr. Li’s ability to analyze global research trends, adding to their scholarly influence.

Education 🎓

  • Ph.D. in Biochemistry and Molecular Biology (2013–2017)
    Central South University, Changsha, Hunan, China
  • B.S. in Biotechnology (2008–2012)
    Changchun University of Technology, Changchun, Jilin, China

Experience 💼

  • Research Scientist (09/2020–Present)
    Hunan Provincial People’s Hospital, Hunan Normal University, Changsha, Hunan, China
  • Postdoctoral Fellow (09/2018–08/2020)
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Instructor (06/2018–06/2020)
    Guangzhou Medical University, Guangzhou, Guangdong, China
  • Technician (08/2012–08/2013)
    Sansure Biotech Inc., Changsha, Hunan, China

Research Interests On Molecular Medicine🔬

Dr. Li’s research spans:

  • Molecular mechanisms in cancer biology 🧬
  • Nephrology, focusing on lupus nephritis and glomerulopathy 🩺
  • Biomarker identification and therapeutic development 🚑

Awards 🏆

  • 2018: Outstanding Graduate
  • 2016-2017: Excellent Graduate Student
  • 2009-2010: Excellent Student and Excellent Student Leader

Publications 📚

  • Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing
    Authors: G Li, X Guo, L Tang, M Chen, X Luo, L Peng, X Xu, S Wang, Z Xiao, W Yi, …
    Year: 2017
    Citations: 43
  • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
    Authors: G Li, X Guo, M Chen, L Tang, H Jiang, JX Day, Y Xie, L Peng, X Xu, J Li, …
    Year: 2018
    Citations: 39
  • What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients
    Authors: W Wang, H Liu, G Li
    Year: 2022
    Citations: 26
  • Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients
    Authors: J Heng, X Guo, W Wu, Y Wang, G Li, M Chen, L Peng, S Wang, L Dai, …
    Year: 2017
    Citations: 20
  • The research landscape of ferroptosis in cancer: a bibliometric analysis
    Authors: G Li, Y Liang, H Yang, W Zhang, T Xie
    Year: 2022
    Citations: 17
  • Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients
    Authors: Y Xie, G Li, M Chen, X Guo, L Tang, X Luo, S Wang, W Yi, L Dai, J Wang
    Year: 2018
    Citations: 16
  • Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients
    Authors: T Xie, M Chen, X Tang, H Yin, X Wang, G Li, J Li, X Zuo, W Zhang
    Year: 2016
    Citations: 16
  • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
    Authors: H Deng, M Chen, X Guo, J Heng, X Xu, L Peng, H Jiang, G Li, JX Day, J Li, …
    Year: 2019
    Citations: 11
  • Bibliometric insights of global research landscape in mitophagy
    Authors: G Li, W Yin, Y Yang, H Yang, Y Chen, Y Liang, W Zhang, T Xie
    Year: 2022
    Citations: 10
  • LINC00467 is upregulated by DNA copy number amplification and hypomethylation and shows ceRNA potential in lung adenocarcinoma
    Authors: W Wang, H Bo, Y Liang, G Li
    Year: 2022
    Citations: 9

Conclusion 📝

Dr. Guoli Li is a passionate scientist and educator committed to advancing medical research and improving clinical outcomes. With numerous prestigious publications, awards, and invitations as a reviewer for reputed journals, Dr. Li continues to contribute profoundly to the global research community. 🌐